Overview of Avoiding, Treating & Curing Cancer With the Immune System | Dr. Alex Marson (Huberman Lab Podcast)
This episode (Andrew Huberman interviewing Dr. Alex Marson, UCSF/Gladstone) covers how the immune system recognizes disease, how cancer arises, and modern tools to prevent and treat cancer — especially immune-based therapies and gene editing (CRISPR, CAR T cells, lipid nanoparticles). The conversation spans immune basics (innate vs adaptive, T cells/B cells/thymus), major cancer risk factors, the clinical successes and limits of immunotherapy (checkpoint inhibitors, CAR T), technical details of CRISPR and delivery methods, translational/ethical issues (germline editing, embryo sequencing), and where the field is headed.
Key topics discussed
- Immune system overview: innate immunity (dendritic cells, macrophages) vs adaptive immunity (T cells, B cells), thymic education and tolerance.
- How cancer develops: accumulation of DNA mutations, evolutionary selection in cells, role of mutagens and inherited predispositions (e.g., BRCA).
- Immunotherapy successes and limits: checkpoint inhibitors (PD-1, CTLA-4), CAR T-cells (CD19 → B-cell leukemias/lymphomas) and challenges for solid tumors.
- Gene editing and CRISPR: mechanism (Cas9 + guide RNA), applications, off-target concerns, newer tools (base editors, epigenetic editors).
- Delivery technologies: lentivirus, electroporation for ex vivo cell editing; lipid nanoparticles (LNPs) and engineered viral tropisms for in vivo delivery.
- Clinical translation & industry examples: Emily Whitehead (first pediatric CAR T success), Arsenal Biosciences, Gladstone/UCSF trials (prostate cancer, multiple myeloma), CAR T for autoimmune disease.
- Ethics & regulation: He Jiankui germline embryo edits; Dr. Marson’s stance against inheritable (germline) edits and concerns about “designer offspring.”
- Near-future trends: single-cell CRISPR screening, AI-designed protein engagers, scalable in vivo delivery, induced pluripotent stem cells (iPSCs) and potential cell banks.
Main takeaways and insights
- Medicine is undergoing a step change: we can now read genomes and directly program cells (CRISPR, CARs, LNP-delivered mRNA), turning biology into programmable medicine.
- The immune system is a powerful, precise tool for targeting disease — and unlocking/redirecting it (checkpoint inhibitors, engineered T cells) has already cured some cancers that were previously fatal.
- CAR T therapy success story: CD19 CAR T for B-cell leukemias (e.g., Emily Whitehead) showed dramatic, sometimes curative, results; collateral loss of normal B cells is tolerable in that context.
- Major limitation for many cancers (especially solid tumors) is finding safe, tumor-specific targets and overcoming the immunosuppressive tumor microenvironment — CRISPR-based multi-gene edits aim to improve T-cell persistence and resistance to tumor defenses.
- CRISPR is powerful and versatile: it enables cutting, precise base changes, and epigenetic regulation. But all editing carries risk (off-target cuts, bystander effects); new tools (base editors, epi-editors) aim to reduce those risks.
- Delivery matters: ex vivo editing (take cells out, edit, return) is proven; in vivo delivery (LNPs, engineered viral vectors, tropism engineering) is rapidly advancing and may enable less invasive, scalable therapies.
- Germline (heritable) editing is ethically fraught; many scientists advocate banning heritable edits while continuing somatic (non-heritable) therapeutic work.
- There is huge momentum from both experimental and computational advances (including AI) enabling faster discovery and more bespoke therapeutics (e.g., AI-designed protein engagers, bispecifics/T-cell engagers).
Immune & cancer basics (concise)
- Innate immune system: first responder cells (macrophages, dendritic cells) detect general danger patterns and signal to other immune components.
- Adaptive immune system: T cells (cell-mediated) and B cells (antibody production). T-cell receptors are generated by somatic recombination (high diversity); thymus performs positive/negative selection to reduce self-reactivity.
- Cancer = genetic disease of cells that lose normal growth control via accumulated mutations; risk increases with age because mutations accumulate over time and through exposure to mutagens.
- Strong, established cancer risk factors: smoking, ultraviolet overexposure (avoid sunburn), some environmental/occupational carcinogens, certain pesticides, ionizing radiation (dose-dependent), obesity and related metabolic states. Diet and other exposures (charred meat, additives) carry risk signals but data are often messy and context-dependent.
Practical, actionable recommendations (what people can do now)
- Avoid clear, high-risk exposures: don’t smoke (or vape as a less‑desirable alternative), avoid sunburns, minimize unnecessary ionizing radiation (only get X‑rays/CTs when medically indicated).
- If you have a family history suggestive of hereditary cancer (e.g., early-onset breast/ovarian cancer), consider genetic counseling and BRCA testing.
- Maintain overall health: healthy diet, manage obesity and metabolic health, good sleep and stress control (sleep correlates strongly with immune health, even if mechanisms are still being studied).
- Use antibiotics appropriately — they are lifesaving for bacterial infections; overuse risks resistance but timely use for bacterial disease is justified.
- Don’t overinterpret single animal studies (high-dose mouse carcinogen data) as direct human hazard without exposure/dose context.
CRISPR, delivery, and therapeutic approaches (summary)
- CRISPR-Cas9 = protein (scissor) + guide RNA that directs the cut. It enabled targeted genome editing broadly because guide RNAs are easy to design and order.
- Precision/imprecision: technology has improved (high-fidelity Cas variants, screening for off-targets), but double-strand breaks can produce unpredictable bystander effects; alternatives include base editors (precise nucleotide changes) and epigenetic editors (no cut).
- Ex vivo workflow (current successful model): harvest patient T cells → edit (lentivirus or electroporated Cas9/protein-RNA complexes) → expand/test → freeze → reinfuse. This is how many CAR T therapies are made.
- In vivo delivery: lipid nanoparticles (LNPs — used in mRNA COVID vaccines) and engineered viral vectors are being adapted to deliver mRNA, protein, or CRISPR to chosen cell types. Targeting/tropism engineering is advancing quickly (including LNPs with targeting ligands, virus-like particles).
- Alternative modular approaches: antibody-drug conjugates, bispecific T-cell engagers (bring endogenous T cells to tumors), radioligand conjugates — all are complementary strategies.
Clinical & translational highlights
- Checkpoint inhibitors (anti–PD-1, anti–CTLA-4) have produced durable remissions in melanoma and other cancers; sometimes cause autoimmune-like side effects because they remove inhibitory brakes on T cells.
- CAR T cells (CD19) are approved for some blood cancers; major challenge is translating to solid tumors because of target specificity and tumor microenvironment.
- CRISPR-engineered CAR T cells and multi-gene edits are in clinical trials (academic and biotech companies like Arsenal and Gladstone-led trials).
- Immunotherapy is also being explored to treat autoimmune diseases (e.g., targeted elimination of disease-driving B cells).
Ethics and societal considerations
- Germline editing (edits passed to offspring) raises major ethical, equity, and diversity concerns. Dr. Marson argues strongly against creating inheritable edits; he supports somatic therapeutic editing.
- Deep embryo/genome sequencing for embryo selection introduces social/ethical questions (reduction of diversity, false promises given probabilistic nature of many genetic variants).
- Accessibility and equity: many advanced therapies are expensive; inequitable access risks widening health disparities (a major societal challenge as these tools scale).
Notable quotes / memorable lines
- “Medicine is programming the behavior of cells in the language of DNA.” — summarizes the central paradigm shift.
- “We can actually talk to our own cells and give them instructions in the language of DNA.” — on therapeutics as programmable biology.
- On germline editing: “We should have a line in the sand where we do not introduce genetic edits that will be passed on to the next generation.”
What to watch next (near-term trends)
- More precise CRISPR tools (base editors, epi-editors) to reduce unintended edits.
- In vivo targeted delivery (LNPs, engineered viral tropisms) that could enable off-the-shelf or less-invasive gene therapies.
- Single-cell CRISPR screens across human primary cells — building functional maps of what genes do in human immune cells (roadmap for rational engineering).
- AI-designed protein therapeutics and synthetic binders for tumor-specific targeting (bispecifics, novel engagers).
- Trials expanding immunotherapy to solid tumors and autoimmune diseases; progress in iPSC-derived immune cells and scalable manufacturing.
Short list of cautions and limits
- Cancer remains probabilistic: even with perfect lifestyle choices, cancer can still occur due to chance mutations.
- CRISPR and editing tools are extremely promising but not risk‑free; thorough evaluation of off-target and long-term consequences is necessary.
- Germline edits and embryo “design” have profound ethical risks; somatic therapies are the accepted, ethical direction today.
Quick action checklist (for non-scientists)
- Stop smoking; avoid vaping if possible.
- Limit sunburns and excessive UV exposure (sensible sun exposure, sunscreen when necessary).
- Get genetic counseling/testing if strong family history of cancer (e.g., BRCA).
- Maintain metabolic health (manage weight, diet, activity, sleep).
- Follow recommended medical care for infections (use antibiotics appropriately).
- Stay informed about clinical trials and advances, but be skeptical of one-off animal studies as direct human risk proof.
If you want a single-line summary: the future of cancer care increasingly relies on harnessing and genetically programming the immune system — CRISPR and advanced delivery systems are enabling precise, durable, and increasingly translatable therapies, while ethical limits (especially around germline editing), delivery challenges, and target selection for solid tumors remain active barriers being actively addressed.